The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase 1 trial of TLR9 agonist lefitolimod in combination with CTLA-4 checkpoint inhibitor ipilimumab in advanced tumors.
 
Matthew Reilley
Travel, Accommodations, Expenses - Deciphera; Xencor
 
Apostolia Maria Tsimberidou
Honoraria - Covance; Genentech
Consulting or Advisory Role - Roche
Research Funding - Baxter (Inst); Bayer (Inst); Boston Biomedical (Inst); EMD Serono (Inst); Foundation Medicine (Inst); IMMATICS (Inst); Karus Therapeutics (Inst); OBI Pharma (Inst); ONYX (Inst); Placon (Inst); Stem Cells, Inc. (Inst)
Patents, Royalties, Other Intellectual Property - Parker Institute for Cancer Immunotherapy (Inst)
 
Sarina Anne Piha-Paul
Research Funding - Abbvie (Inst); Aminex (Inst); Bayer (Inst); BlueLink (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Cerulean Pharma (Inst); Chugai Pharma (Inst); Curis (Inst); Five Prime Therapeutics (Inst); Genmab (Inst); GlaxoSmithKline (Inst); Helix BioPharma (Inst); Incyte (Inst); Jacobio (Inst); MedImmune (Inst); Medivation (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Pfizer (Inst); Pieris Pharmaceuticals (Inst); Principa Biopharma (Inst); Puma Biotechnology (Inst); Samumed (Inst); Seagen (Inst); Taiho Pharmaceutical (Inst); Tesaro (Inst); TransThera Biosciences (Inst); TransThera Biosciences (Inst); XuanZhu (Inst)
 
Timothy A Yap
Honoraria - AstraZeneca; Pfizer
Consulting or Advisory Role - Aduro Biotech; Almac Diagnostics; AstraZeneca; Atrin Pharmaceuticals; Bayer; Bristol-Myers Squibb; Calithera Biosciences; Clovis Oncology; Cybrexa Therapeutics; EMD Serono; Ignyta; Janssen; Merck; Pfizer; Roche; Seagen; Tesaro; Vertex
Speakers' Bureau - AstraZeneca
Research Funding - AstraZeneca; Bayer; Constellation Pharmaceuticals; Jounce Therapeutics; Kyowa Hakko Kirin; Lilly; Pfizer; Seagen; Tesaro; Vertex
Patents, Royalties, Other Intellectual Property - MD Anderson Cancer Center holds the intellectual property rights to IACS-010759 and its designated use. (Inst)
Travel, Accommodations, Expenses - EMD Serono; Pfizer; Tesaro
 
Siqing Fu
Research Funding - Anaeropharma (Inst); Aprea Therapeutics (Inst); AstraZeneca (Inst); BeiGene (Inst); BioAtla (Inst); Boehringer Ingelheim (Inst); Endocyte (Inst); Huya Bioscience International (Inst); Lilly (Inst); MacroGenics (Inst); Medivir (Inst); NeuPharma, Inc. (Inst); Novartis (Inst); OncoMed (Inst); Parexel International, LLC (Inst); Takeda (Inst)
 
Aung Naing
Consulting or Advisory Role - CytomX Therapeutics; Novartis
Research Funding - Amplimmune; ARMO BioSciences; Atterocor; Bristol-Myers Squibb; Calithera Biosciences; CytomX Therapeutics; EMD Serono; Healios; Immune Cell Therapy (I); Incyte; Karyopharm Therapeutics; Kyocera; Lilly; MedImmune; Merck; NCI; Neon Therapeutics; Novartis; Pfizer; Regeneron; TopAlliance BioSciences Inc
Travel, Accommodations, Expenses - ARMO BioSciences
 
Jordi Rodon
No Relationships to Disclose
 
Ly Minh Nguyen
No Relationships to Disclose
 
Casey Ager
No Relationships to Disclose
 
Martin Meng
No Relationships to Disclose
 
Priyamvada Jayaprakash
No Relationships to Disclose
 
Manuel Schmidt
Employment - MOLOGEN
Leadership - MOLOGEN
Stock and Other Ownership Interests - MOLOGEN
 
Matthias Baumann
Employment - MOLOGEN
Leadership - MOLOGEN
Stock and Other Ownership Interests - MOLOGEN
 
Funda Meric-Bernstam
Honoraria - Dialectica; Sumitomo Group
Consulting or Advisory Role - Aduro Biotech; Clearlight Diagnostics; DarwinHealth; Debiopharm Group; Genentech; Inflection Biosciences; Mersana; Origimed; Pieris Pharmaceuticals; Samsung Bioepis; Spectrum Pharmaceuticals; Xencor
Research Funding - Abbvie; Aileron Therapeutics; AstraZeneca; Bayer; Boehringer Ingelheim (I); Calithera Biosciences; Curis; CytomX Therapeutics; Daiichi Sankyo; Debiopharm Group; eFFECTOR Therapeutics; Genentech; GlaxoSmithKline; Guardant Health (Inst); Jounce Therapeutics; Novartis; Pfizer; PUMA Biotechnology; Taiho Pharmaceutical; Zymeworks
 
Michael A. Curran
Research Funding - AstraZeneca; Bristol-Myers Squibb
 
David S. Hong
Stock and Other Ownership Interests - MolecularMatch; Oncorena; Presagia
Honoraria - Adaptimmune; Baxter; Bayer; Merrimack
Consulting or Advisory Role - Adaptimmune; Alphasights; Axiom Biotechnologies; Baxter; Bayer; Eisai; Genentech; Gerson Lehrman Group; GroupH; Guidepoint Global; Janssen; Medscape; Merrimack; Numab; Pfizer; Seagen; Takeda; Trieza Therapeutics
Research Funding - Abbvie; Adaptimmune; Amgen; Amgen; AstraZeneca; Bayer; Bristol-Myers Squibb; Daiichi Sankyo; Eisai; Fate Therapeutics; Genentech; Genmab; Ignyta; Infinity Pharmaceuticals; Kite, a Gilead company; Kyowa Hakko Kirin; Lilly; Loxo; MedImmune; Merck; Mirati Therapeutics; miRNA Therapeutics; Molecular Templates; MOLOGEN; National Cancer Institute; Novartis; Pfizer; Seagen; Takeda
Travel, Accommodations, Expenses - Genmab; Loxo; miRNA Therapeutics